Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?

Cancer Chemotherapy and Pharmacology

Volumn 78, Issue 5, 2016, Pages 1097-1098

  Srinivas, Nuggehally R ^a  

^a Suramus Bio   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DOCETAXEL; DOXORUBICIN; NAVELBINE; TARIQUIDAR; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; QUINOLINE DERIVATIVE;

BILIARY EXCRETION; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; INTESTINAL REABSORPTION; LETTER; LIVER METABOLISM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RENAL CLEARANCE; SYSTEMIC CIRCULATION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; HUMANS; P-GLYCOPROTEIN; QUINOLINES;

EID: 84968624025     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3044-4     Document Type: Letter

References (13)

1. Fox E, Widemann BC, Pastakia D et al (2015) Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 76:1273–1283
2. Bruno R, Sanderink GJ (1993) Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 17:305–313
3. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99–114
4. van Zuylen L, Verweij J, Nooter K et al (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6:2598–2603
5. Kelly RJ, Draper D, Chen CC et al (2011) A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17:569–580
6. Levêque D, Jehl F (1996) Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 31:184–197
7. Wargin WA, Lucas VS (1994) The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 21(5 Suppl 10):21–27
8. Levêque D, Merle-Melet M, Bresler L et al (1993) Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemother Pharmacol 32:487–490
9. Abraham J, Edgerly M, Wilson R et al (2009) A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 15:3574–3582
10. Mross K, Mayer U, Langenbuch T, Hamm K, Burk K, Hossfeld D (1990) Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients. Eur J Cancer 26:1156–1162
11. Ballet F, Vrignaud P, Robert J, Rey C, Poupon R (1987) Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver. Cancer Chemother Pharmacol 19:240–245
12. Camaggi CM, Strocchi E, Comparsi R, Testoni F, Angelelli B, Pannuti F (1986) Biliary excretion and pharmacokinetics of 4’epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol 18:47–50
13. Asakura E, Nakayama H, Sugie M et al (2004) Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol 484:333–339